IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 4187 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
  Search
 
  
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Article in PDF (1,477 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

 
  In this article
   References
   Article Figures

 Article Access Statistics
    Viewed1415    
    Printed24    
    Emailed1    
    PDF Downloaded45    
    Comments [Add]    

Recommend this journal

 


 
 Table of Contents    
LETTER TO THE EDITOR
Year : 2014  |  Volume : 80  |  Issue : 6  |  Page : 568-569

Hidradenocarcinoma of the chest


Department of Dermatology, Santo António dos Capuchos Hospital, Centro Hospitalar Lisboa Central, Lisbon, Portugal

Date of Web Publication7-Nov-2014

Correspondence Address:
Ana Brasileiro
Department of Dermatology, Hospital Santo António dos Capuchos, Centro Hospitalar Lisboa Central, Lisbon
Portugal
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0378-6323.144215

Rights and Permissions



How to cite this article:
Brasileiro A, Lencastre A, Joao A, Apetato M. Hidradenocarcinoma of the chest . Indian J Dermatol Venereol Leprol 2014;80:568-9

How to cite this URL:
Brasileiro A, Lencastre A, Joao A, Apetato M. Hidradenocarcinoma of the chest . Indian J Dermatol Venereol Leprol [serial online] 2014 [cited 2020 Apr 6];80:568-9. Available from: http://www.ijdvl.com/text.asp?2014/80/6/568/144215


Sir,

Sweat gland tumors, especially those of a malignant nature remain an elusive area of knowledge for dermatologists, oncologists and pathologists. Due to the paucity of published literature, there is not only a lack of consensus over histopathological classification but also on their optimal management. We report a middle-aged patient with clear cell hidradenocarcinoma who was successfully treated with wide local excision and sentinel lymph node dissection.

A 49-year-old male reported a 13-month history of an asymptomatic, ulcerated, pink exophytic nodule measuring 3 cm in diameter and located on the right parasternal area [Figure 1]. His past medical history was non-contributory though he stated that a similar lesion was present 8 months ago which was excised at another center and whose histology results he was not aware of. He described a rapid relapse and growth of the lesion soon after this procedure. Surgical excision with 2 cm margins revealed a poorly circumscribed ulcerated tumor in continuity with the epidermis [Figure 2], with large cords and confluent areas of basaloid cells, occupying the entire dermis and part of the hypodermis [Figure 3]. Several areas of necrosis and mitoses were observed within the tumor limits. Cells were AE1/AE3 positive; epithelial membrane antigen (EMA) and carcinoembryonic antigen (CEA) negative. Sentinel lymph node biopsy was negative. Thoraco-abdomino-pelvic computed tomography did not show any pathological findings. In view of the lack of local or distant metastasis, local widening of the tumor bed was performed such that no residual tumor was detected. The patient remains disease free for the past 24 months.
Figure 1: Pink ulcerated nodule on the chest. The preceding surgery scar can be seen in the background

Click here to view
Figure 2: Poorly circumscribed ulcerated tumor with several areas of necrosis (H and E, ×10)

Click here to view
Figure 3: Large cords and confluent areas of basaloid cells, some with cytoplasmatic vacuoles. In addition, there are areas with clear cells, atypical cells, and cystic spaces filled with eosinophilic material (H and E, ×200)

Click here to view


Clear cell hidradenocarcinoma is one of the most common forms of the rare eccrine sweat gland carcinomas. It arises from the eccrine apparatus and is known for aggressive behavior with high rates of local recurrences and metastases. Clinically, it appears most commonly on the face, hands, or feet, starting as an asymptomatic solitary skin lesion with a pink, blue, or purple surface, which may ulcerate. It usually expands slowly, but sudden spontaneous spurts of growth may occur. [1] Lack of any characteristic clinical findings usually leads to a delay in the diagnosis by which time the loco-regional spread to lymph nodes or visceral metastasis to bone and lungs may have already occurred, making the course and prognosis of clear cell hidradenocarcinoma different from the commoner skin tumors. Only the "accelerated" growth mentioned by the patient raised our suspicion in this case, as the location was also not typical.

On histology, sheets of pale, glycogen-rich cells form the tumor. Rudimentary lumina formation within cells seen as intracellular vacuoles are an important feature, as is the cyto-architectural atypia. The number of mitoses and degree of atypia varies and some tumors may have a deceptively innocent appearance. [2] Usually, tumors express CK5, CK7, and AE1/AE3 antigens. CEA and EMA expression is variable. [3] The treatment needs to be individualized and decisions are taken on a case-to-case basis relying on the experience of the attending physician. Surgical technique and adjuvant radiotherapy or chemotherapy all remain areas of controversy. [1],[2] We opted to widen the primary tumor margins with sentinel lymph node dissection when marginal tumor remnants were observed on the first histological examination. The use of radiotherapy has been demonstrated to be useful in cases of moderately to poorly differentiated tumors. [1] Chemotherapy with capecitabine has been reportedly useful in a few cases of extensively metastatic disease. [4] Recently published research points towards a potential role for targeted therapy in metastasizing adnexal carcinomas. [2],[5] Further work needs to be done to assess their applicability in this setting.



 
  References Top

1.
Souvatzidis P, Sbano P, Madato F, Fimiani M, Castelli A. Malignant nodular hidradenoma of the skin: Report of seven cases. J Eur Acad Dermatol Venereol 2008;22:549-54.  Back to cited text no. 1
    
2.
Gauerke S, Driscoll JJ. Hidradenocarcinomas - A brief review and future directions. Arch Pathol Lab Med 2010;134:781-5.  Back to cited text no. 2
    
3.
Ko CJ, Cochran AJ, Eng W, Binder SW. Hidradenocarcinoma: A histological and immunohistochemical study. J Cutan Pathol 2006;33:726-30.  Back to cited text no. 3
    
4.
Lerner A, Beckford A, Ugent S, Goldberg L, Jalisi S, Demierre MF. Complete response of metastatic malignant hidradenocarcinoma to capecitabine treatment. Arch Dermatol 2011;147:998-9.  Back to cited text no. 4
    
5.
Dias-Santagata D1, Lam Q, Bergethon K, Baker GM, Iafrate AJ, Rakheja D, etal. A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas. Modern Pathol 2011;24:974-82.  Back to cited text no. 5
    


    Figures

  [Figure 1], [Figure 2], [Figure 3]



 

Top
Print this article  Email this article

    

Online since 15th March '04
Published by Wolters Kluwer - Medknow